French biotech Enterome has signed a strategic R&D collaboration and license agreement with Switzerland’s Nestlé Health Science.
Part of a new wave of companies interested in the microbiome, Enterome has been working on its Mimicry drug discovery platform, leveraging interactions between the gut microbiome and the immune system.
The platform uses biocomputational tools and bioassays to identify novel therapeutics for a broad range of indications, using a proprietary database of over 20 million peptides and proteins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze